Immunoglobulin Use for the Management of Painful Peripheral Neuropathy: A Systematic Review and Meta-Analysis

[1]  S. V. van Kuijk,et al.  Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy , 2021, Neurology.

[2]  H. Hartung,et al.  Patient‐reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study , 2020, European journal of neurology.

[3]  C. Tufanaru,et al.  Methodological quality of case series studies: an introduction to the JBI critical appraisal tool , 2019, JBI database of systematic reviews and implementation reports.

[4]  R. Treister,et al.  IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety , 2018, Therapeutic advances in neurological disorders.

[5]  S. Kaveri,et al.  IVIG-mediated effector functions in autoimmune and inflammatory diseases , 2017, International immunology.

[6]  A. Schenone,et al.  High-Dose Intravenous Immunoglobulin Is Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. , 2016, Pain medicine.

[7]  K. Wilhelmsen,et al.  Intravenous immunoglobulin skews macrophages to an anti‐inflammatory, IL‐10‐producing activation state , 2015, Journal of leukocyte biology.

[8]  M. Vermeulen,et al.  Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  Stefano Tamburin,et al.  Immunoglobulin g for the treatment of chronic pain: report of an expert workshop. , 2014, Pain medicine.

[10]  S. Kaveri,et al.  Natural Autoantibodies to Fcγ Receptors in Intravenous Immunoglobulins , 2014, Journal of Clinical Immunology.

[11]  S. Kaveri,et al.  The mechanisms of action of IVIG in autoimmune and inflammatory diseases , 2013 .

[12]  K. Gorson.  An update on the management of chronic inflammatory demyelinating polyneuropathy , 2012, Therapeutic advances in neurological disorders.

[13]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[14]  C. Karam.  Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy , 2010, Neurology.

[15]  L. H. van den Berg,et al.  Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy , 2010, Journal of Clinical Immunology.

[16]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[17]  W. Oertel,et al.  Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy , 2009, Proceedings of the National Academy of Sciences.

[18]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[19]  M. Dalakas.  Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies , 2002, Neurology.

[20]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[21]  J. Cavaillon,et al.  Selective induction of interleukin‐1 receptor antagonist and interleukin‐8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin) , 1995, European journal of immunology.

[22]  C. Tufanaru,et al.  Chapter 7: Systematic Reviews of Etiology and Risk , 2020, JBI Manual for Evidence Synthesis.

[23]  C. Bias.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .